Pacira BioSciences, Inc. (PCRX): who owns it and who trades it
As of Nov 16, 2026, PCRX insiders reported 16 open-market sales worth $2.5M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Shawn Cross (CFO), with $1.3M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Pacira BioSciences
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns PCRX
251 funds and institutions reported PCRX shares worth $1.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 17.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 6.71M | 17.04% | $170M | -0% |
| Doma Perpetual Capital Management LLC | 2.78M | 7.06% | $70.5M | No change |
| Vanguard Portfolio Management LLC | 2.41M | 6.12% | $61M | -4% |
| Dimensional Fund Advisors LP | 2.10M | 5.35% | $53.4M | +2% |
| State Street Corp | 2.06M | 5.24% | $52.3M | +7% |
| D. E. Shaw & Co., Inc. | 1.95M | 4.96% | $49.5M | -2% |
| Renaissance Technologies LLC | 1.73M | 4.41% | $44M | -5% |
| Vanguard Capital Management LLC | 1.69M | 4.30% | $42.9M | -5% |
| Goldman Sachs Group Inc | 1.53M | 3.88% | $38.7M | -3% |
| California State Teachers Retirement System | 1.52M | 3.87% | $60M | +2383% |
| Geode Capital Management, LLC | 1.16M | 2.94% | $29.4M | +1% |
| Morgan Stanley | 1.14M | 2.91% | $29M | -18% |
| American Century Companies Inc | 1.02M | 2.59% | $25.8M | +22% |
| UBS Group AG | 920,217 | 2.34% | $23.3M | +64% |
| Impax Asset Management Group plc | 750,027 | 1.91% | $19M | No change |
| Two Sigma Investments, LP | 724,604 | 1.84% | $18.4M | +38% |
| Charles Schwab Investment Management Inc | 690,786 | 1.76% | $17.5M | -6% |
| Sixth Street Partners Management Company, L.P. | 690,786 | 1.76% | $17.5M | – |
| Gagnon Securities LLC | 608,617 | 1.55% | $15.4M | -1% |
| Lsv Asset Management | 608,376 | 1.55% | $15.4M | +18% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, PCRX insiders reported $0 of open-market purchases and $2.5M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | Lauren Riker | Vice president | Sale plan | 6,000 | $36.32 | $218K | Form 4 |
| Aug 17, 2026 | Jonathan Slonin | Chief Medical Officer | Sale plan | 3,040 | $23.23 | $70.6K | Form 4 |
| Jun 11, 2026 | Lauren Riker | Vice president | Sale plan | 6,115 | $23.50 | $144K | Form 4 |
| Jun 4, 2026 | Kristen Williams | Chief Administrative Off | Sale plan | 10,259 | $22.27 | $228K | Form 4 |
| Apr 23, 2026 | Shawn Cross | CFO | Sale plan | 12,941 | $25.16 | $326K | Form 4 |
| Apr 22, 2026 | Shawn Cross | CFO | Sale plan | 1,500 | $25.01 | $37.5K | Form 4 |
| Apr 21, 2026 | Shawn Cross | CFO | Sale plan | 2,845 | $25.01 | $71.2K | Form 4 |
| Apr 20, 2026 | Shawn Cross | CFO | Sale plan | 7,714 | $25.14 | $194K | Form 4 |
| Mar 17, 2026 | Jonathan Slonin | Chief Medical Officer | Sale plan | 3,261 | $22.82 | $74.4K | Form 4 |
| Mar 17, 2026 | Mark Froimson | Director | Sale | 500 | $21.81 | $10.9K | Form 4 |
| Feb 2, 2026 | Lauren Riker | Vice president | Sale plan | 4,000 | $20.81 | $83.2K | Form 4 |
| Feb 2, 2026 | Kristen Williams | Chief Administrative Off | Sale plan | 13,137 | $20.53 | $270K | Form 4 |
| Jan 5, 2026 | Lauren Riker | Vice president | Sale plan | 1,416 | $24.24 | $34.3K | Form 4 |
| Dec 10, 2025 | Shawn Cross | CFO | Sale plan | 9,104 | $25.14 | $229K | Form 4 |
| Dec 9, 2025 | Shawn Cross | CFO | Sale plan | 15,896 | $25.03 | $398K | Form 4 |
| Nov 17, 2025 | Jonathan Slonin | Chief Medical Officer | Sale plan | 3,960 | $24.09 | $95.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Shawn Cross | Chief Financial Officer | – | $1.3M | Apr 23, 2026 |
| Kristen Williams | Chief Administrative Officer | – | $498K | Jun 4, 2026 |
| Lauren Riker | Senior Vice President, Finance | – | $479K | Oct 8, 2026 |
| Jonathan Slonin | Chief Medical Officer | – | $240K | Aug 17, 2026 |
| Mark Froimson | Director | – | $10.9K | Mar 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PCRX short interest
Moderate short interest. 8.4% of PCRX shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 52%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.35M PCRX shares were sold short, 8.4% of the shares outstanding, down 21.4% from the report before. At the average daily volume of 855,601 shares, buying them all back would take about 3.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.35M | 8.40% | -21% | 855,601 | 3.9 |
| Oct 15, 2026 | 4.26M | 10.69% | -47% | 3.93M | 1.1 |
| Sep 30, 2026 | 8.08M | 20.26% | +7% | 536,467 | 15.1 |
| Sep 15, 2026 | 7.56M | 18.97% | +3% | 582,564 | 13.0 |
| Aug 31, 2026 | 7.33M | 18.38% | +0% | 432,362 | 16.9 |
| Aug 14, 2026 | 7.30M | 18.31% | +1% | 902,817 | 8.1 |
| Jul 31, 2026 | 7.21M | 18.33% | +4% | 538,752 | 13.4 |
| Jul 15, 2026 | 6.96M | 17.70% | +6% | 441,184 | 15.8 |
| Jun 30, 2026 | 6.59M | 16.74% | +5% | 565,399 | 11.7 |
| Jun 15, 2026 | 6.28M | 15.95% | -5% | 376,108 | 16.7 |
| May 29, 2026 | 6.60M | 16.76% | -6% | 469,036 | 14.1 |
| May 15, 2026 | 6.99M | 17.76% | -10% | 680,534 | 10.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Pacira BioSciences company events
Pacira BioSciences filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementShared information with investors. Filing
- Oct 8, 2026AgreementPacira BioSciences, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Viatris Inc., a Delaware corporation, and Peach Purchaser Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jun 30, 2026AgreementPacira BioSciences, Inc. and Pacira CryoTech, Inc., the Company’s wholly owned subsidiary, entered into a Stock and Asset Purchase Agreement with Zimmer, Inc., a subsidiary of Zimmer Biomet Holdings, Inc. Filing
- Jun 11, 2026LeadershipPacira BioSciences, Inc. held its 2026 Annual Meeting of Stockholders in Parsippany, New Jersey and via live webcast online at www.cesonlineservices.com/pcrx26_vm, at which the Company’s stockholders approved the Amended and Restated 2014 Employee Stock Purchase Plan. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 28, 2026LeadershipThe Board of Directors of Pacira BioSciences, Inc., pursuant to the Amended and Restated Certificate of Incorporation of the Company and the Third Amended and Restated Bylaws of the Company, approved an increase of the size of the Board from nine directors to 10 directors, and appointed Dr. Samit… Filing
- Jan 8, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Pacira BioSciences financials
Famous investors that hold PCRX
3 of the 50 well-known investors we track reported holding PCRX in their latest 13F filing. The largest position is Jim Simons's, worth $41.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.67M | $41.9M | 0.1% | -4% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 53,708 | $1.3M | 0.0% | -67% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 13,718 | $344K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PCRX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 4.8% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 4.8% |
| Oct 13, 2026 | Doma Perpetual Capital Management LLC | 13D/A | 0.0% |
| Oct 13, 2026 | Doma Perpetual Capital Management LLC | 13D/A | 0.0% |
Questions about Pacira BioSciences, Inc. (PCRX) stock
Who owns the most PCRX stock?
The largest reported owner of Pacira BioSciences, Inc. (PCRX) is BlackRock, Inc., with 17.0% of the company. In total, 251 funds and institutions reported holding PCRX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are PCRX insiders buying or selling?
In the last 12 months, PCRX insiders reported no open-market purchases and 16 sales worth $2.5M. The latest trade was on Oct 8, 2026. See every trade.
What is the short interest in PCRX?
As of Oct 30, 2026, 3.35M PCRX shares were sold short, 8.4% of the shares outstanding, down 21.4% from the report before. At the average daily volume of 855,601 shares, buying them all back would take about 3.9 trading days (days to cover). See the history.
Which famous investors hold PCRX?
3 of the 50 well-known investors we track reported PCRX in their latest 13F filing, including Jim Simons, Ken Griffin, Paul Tudor Jones. The largest position is worth $41.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.